Assay News and Research

RSS

NIH RADx initiative announces $77.7 million to develop new rapid COVID-19 diagnostic tests

The NIH Rapid Acceleration of Diagnostics (RADx) initiative announced today that it has issued contract awards totaling $77.7 million to develop and manufacture 12 new rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19.

15 Oct 2021

Study reveals a highly effective COVID-19 screening system utilizing a live cell-based assay

A new study reports a cell-based assay that involved the isolation and quantification of SARS-CoV-2 Mpro in human cells in the absence of other proteins.

14 Oct 2021

Assay for the sensitive and specific identification of SARS-CoV-2 Delta variant

Scientists described a quick and inexpensive method for accurately identifying the Delta variant by applying the double-mismatch allele-specific RT-PCR (DMAS-RT-PCR).

14 Oct 2021

New study finds SARS-CoV-2 causes retinal infection

Can coronavirus disease 2019 (COVID-19) affect the eye? New research suggests the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can enter the eye and infect photoreceptor and retinal ganglion cells. In addition, SARS-CoV-2 infection increases the expression of several inflammatory genes, including the cytokine interleukin 33 (IL33), which is linked to COVID-19 disease and retinal degeneration.

13 Oct 2021

Role of CRISPR-Cas12a visual biosensor in detection of SARS-CoV-2

A new study aimed to develop a novel CRISPR-Cas12a powered visual biosensor for the detection of SARS-CoV-2.

13 Oct 2021

New high-throughput assay could help development of anti-COVID-19 drugs

In a recent study, researchers develop a new high-throughput assay that allows for rapid screening of potential inhibitors.

13 Oct 2021

Rapid measurement of SARS-CoV-2 spike T-cells

Researchers measure SARS-CoV-2 T-cell responses in individuals vaccinated or in those who developed immunity from a prior natural infection.

12 Oct 2021

A mucoadhesive polymer with anti-SARS-COV-2 activity in vitro and in vivo

The team has evaluated a low molecular weight chitosan derivative as a candidate preventing the viral entry into mammalian nasal epithelial cells to limit the spread of COVID-19.

12 Oct 2021

A new bacterial two-hybrid assay to study SARS-CoV-2 interactome

Recently, scientists have developed a bacterial two-hybrid (B2H) system to study the PPIs of SARS-CoV-2 in a heterologous non-eukaryotic system. This study is available on the bioRxiv* preprint server. Put simply, the B2H system could be used to analyze the SARS-CoV-2 proteome.

11 Oct 2021

SARS-CoV-2 immune responses in nursing home residents after full vaccination with Pfizer-BioNTech COVID-19 vaccine

A new study assesses antibody and functional T-cell responses at 6 months after complete vaccination with the Pfizer-BioNTech vaccine.

11 Oct 2021

Antibody validation and rapid peptide mapping technology

In this interview, News-Medical speaks to Bin Ma, President of Rapid Novor, about antibody validation and rapid peptide mapping technology.

From Rapid Novor Inc 11 Oct 2021

The role of inhibiting palmitoylation of the SARS-CoV-2 spike protein on viral infectivity

It is demonstrated that palmitoylation of the first five cysteine residues of the C-terminal domain of the SARS-CoV-2 spike protein facilitates cell entry and the formation of syncytia.

11 Oct 2021

Vaccine-induced memory B cells can recognize SARS-CoV-2 variants

Researchers have been investigating the effect that memory B cells produced in individuals who have received an mRNA vaccine have against SARS-CoV-2 variants.

11 Oct 2021

Sero-epidemiological insights into pathways to COVID-19 immunity

A new study posted to the medRxiv* server attempts to utilize serology as a tool to identify disparities in infection rates and vaccination coverage.

10 Oct 2021

Research finds different antibody responses following COVID vaccination and natural infection

A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth.

10 Oct 2021